4‑(Difluoromethyl)-5-(4-((3R,5S)‑3,5-dimethylmorpholino)-6-((R)‑3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders.

MLA

Borsari, Chiara, et al. “4‑(Difluoromethyl)-5-(4-((3R,5S)‑3,5-Dimethylmorpholino)-6-((R)‑3-Methylmorpholino)-1,3,5-Triazin-2-Yl)Pyridin-2-Amine (PQR626), a Potent, Orally Available, and Brain-Penetrant MTOR Inhibitor for the Treatment of Neurological Disorders.” Journal of Medicinal Chemistry, vol. 63, no. 22, Nov. 2020, pp. 13595–617. EBSCOhost, https://doi.org/10.1021/acs.jmedchem.0c00620.

APA

Borsari, C., Keles, E., Rageot, D., Treyer, A., Bohnacker, T., Bissegger, L., De Pascale, M., Melone, A., Sriramaratnam, R., Beaufils, F., Hamburger, M., Hebeisen, P., Löscher, W., Fabbro, D., Hillmann, P., & Wymann, M. P. (2020). 4‑(Difluoromethyl)-5-(4-((3R,5S)‑3,5-dimethylmorpholino)-6-((R)‑3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders. Journal of Medicinal Chemistry, 63(22), 13595–13617. https://doi.org/10.1021/acs.jmedchem.0c00620

Chicago

Borsari, Chiara, Erhan Keles, Denise Rageot, Andrea Treyer, Thomas Bohnacker, Lukas Bissegger, Martina De Pascale, et al. 2020. “4‑(Difluoromethyl)-5-(4-((3R,5S)‑3,5-Dimethylmorpholino)-6-((R)‑3-Methylmorpholino)-1,3,5-Triazin-2-Yl)Pyridin-2-Amine (PQR626), a Potent, Orally Available, and Brain-Penetrant MTOR Inhibitor for the Treatment of Neurological Disorders.” Journal of Medicinal Chemistry 63 (22): 13595–617. doi:10.1021/acs.jmedchem.0c00620.